These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15875323)

  • 1. Immunization coverage against invasive pneumococcal disease among children in the Capital Health Region of Alberta.
    Can Commun Dis Rep; 2005 Mar; 31(6):65-8. PubMed ID: 15875323
    [No Abstract]   [Full Text] [Related]  

  • 2. Invasive pneumococcal infection in first nations children in northern Alberta.
    Vaudry W; Talling D
    Can Commun Dis Rep; 2002 Oct; 28(20):165-72. PubMed ID: 12402519
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005).
    Can Commun Dis Rep; 2006 Jul; 32(14):157-61. PubMed ID: 16869067
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with pneumococcal conjugate vaccine in Norway.
    Aaberge IS
    Expert Rev Vaccines; 2009 Feb; 8(2):159-65. PubMed ID: 19196196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal vaccination: effective in children under the age of 2 years.
    Prescrire Int; 2009 Dec; 18(104):266. PubMed ID: 20027709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.
    Hennessy TW; Singleton RJ; Bulkow LR; Bruden DL; Hurlburt DA; Parks D; Moore M; Parkinson AJ; Schuchat A; Butler JC
    Vaccine; 2005 Dec; 23(48-49):5464-73. PubMed ID: 16188350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Declining invasive pneumococcal disease in the U.S. elderly.
    McBean AM; Park YT; Caldwell D; Yu X
    Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
    Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
    Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing epidemiology of invasive pneumococcal disease: a complicated story.
    Black S
    Clin Infect Dis; 2008 Aug; 47(4):485-6. PubMed ID: 18627248
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunisation coverage in Australian Indigenous children: Time to move the goal posts.
    O'Grady KA; Krause V; Andrews R
    Vaccine; 2009 Jan; 27(2):307-12. PubMed ID: 18977263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rwanda launches vaccination drive against pneumococcal disease in under 5s.
    Moszynski P
    BMJ; 2009 Apr; 338():b1729. PubMed ID: 19398482
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia?
    Giele C; Moore H; Bayley K; Harrison C; Murphy D; Rooney K; Keil AD; Lehmann D
    Vaccine; 2007 Mar; 25(13):2379-84. PubMed ID: 17064825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An expanded pneumococcal vaccine (prevnar 13) for infants and children.
    Med Lett Drugs Ther; 2010 Aug; 52(1345):67-8. PubMed ID: 20724965
    [No Abstract]   [Full Text] [Related]  

  • 19. ACIP extends delay in pneumococcal immunization of healthy children.
    Am J Health Syst Pharm; 2002 Feb; 59(3):228. PubMed ID: 11862630
    [No Abstract]   [Full Text] [Related]  

  • 20. Pneumococcal vaccination for healthy elderly: a comment.
    van den Bosch WJ
    Neth J Med; 2004 Feb; 62(2):66-8. PubMed ID: 15127835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.